← All Telesis Bio INC filings

Telesis Bio INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
TBIO
Telesis Bio INC
10-Q: Telesis Bio Inc. Reports Third Quarter 2024 Results Amidst Strategic Shift
Telesis Bio Inc. reports a net loss of $6.6 million for the third quarter of 2024, alongside the sale of its Eton subsidiary and a shift to the OTC Pink market.
OTC.Pink
TBIO
Telesis Bio INC
10-Q: Telesis Bio Reports Q2 2024 Results Amidst Strategic Shift and Financial Restructuring
Telesis Bio's Q2 2024 results reflect a period of strategic transition, including the divestiture of EtonBio, and financial restructuring efforts.
OTC.Pink
TBIO
Telesis Bio INC
10-Q: Telesis Bio Reports Q1 2024 Results: Revenue Declines Amidst Cost-Cutting Measures
Telesis Bio's first quarter 2024 results show a decrease in revenue compared to the same period last year, alongside reduced operating expenses and a net loss of $8.6 million.